



# The role of financial fragility & travel distance in colorectal cancer patients from rural populations



Jaleyca Foster, Tyler Mouw, MD, Michael Egger, MD, MPH Robert CG Martin II, MD, PhD  
 Department of Surgery, Division of Surgical Oncology, University of Louisville, Louisville, KY

## Introduction


- Colorectal cancer (CRC) is the second most common cause of cancer-related death in the US.
- Rural patients are at a 4% higher risk of death from cancer vs urban patients.
- In the US, median travel time to academic based care is 30 minutes (IQR, 13–72 minutes.)
- Rural patients travel on average 19 miles more to seek care vs urban patients.
- Financial fragility is a measure of an accumulation of resource deficits (financial means & educational attainment) and inconveniencing factors (travel burden, facility type, residential location) that impedes prompt initiation & continuation of care, which in turn leads to adverse health outcomes.

## Purpose

- Evaluate the influence of travel distance and accumulation of deficits that serve as a barrier to initiating CRC care in stages I – III by using FF as a predictive model.
- Assess and compare cancer care between rural and urban populations.

## Methods


- A literature was performed using PubMed, Library of Congress, LISTA (EBSCO) and Web of Science. Keywords included: “Travel distance”, “Colorectal Cancer” and “Access to care” in all fields.
- National Cancer Data Base (NCDB) 4 variables encompass FF; distance traveled, educational attainment, median income, population type.
- Analysis of UofL Brown Cancer and NCDB center via SPSS.
- NCDB was used to identify 90,000 patients with stage 1-2 colon cancer and 67,000 with stage 1-2 rectal to cancer to compare completion of recommended therapies between rural/urban/metro populations.
- For UofL data case control matching was performed to produce urban and rural cohorts to assess the proportion of patients receiving stage-appropriate therapies.



**Figure 1. Kentucky patients limited access to academic care.**  
 The University of Kentucky (Fayette) & the University of Louisville (Jefferson) are the only in state options for patients to receive academic care. As border states OH & TN offer care from the University of Cincinnati & Vanderbilt University. On average in the US, traveling to an academic center takes 30 mins (IQR 13 mins – 72 min.) Travel time (driving) to respective centers is represented by the circles. Dark blue represents 30 minutes and light blue represents 72 minutes.

| Table 2. Univariate Analysis    | Univariate (OR)       | p value        | Multivariate (OR)     | p value        |
|---------------------------------|-----------------------|----------------|-----------------------|----------------|
| <b>Median Distance traveled</b> | 0.991 (0.989 – 0.993) | Less than 0.01 |                       | Less than 0.01 |
| <b>Facility Type</b>            |                       |                |                       |                |
| Community Center (Ref.)         |                       |                |                       |                |
| Comprehensive Community         | 1.097 (0.963 – 1.041) | Less than 0.01 | 1.196 (1.155 – 1.238) | Less than 0.01 |
| Academic Center                 | 0.959 (0.966 – 1.046) | 0.007          | 1.008 (0.972 – 1.046) | Less than 0.01 |
| Integrated Cancer Network       | 1.133 (0.891 – 0.980) | Less than 0.01 | 1.228 (1.181 – 1.276) | Less than 0.01 |
| <b>Race</b>                     |                       |                |                       |                |
| White (Ref.)                    |                       |                |                       |                |
| Black                           | 0.879 (0.857 – 0.903) | Less than 0.01 | 0.775 (0.750 – 0.801) | Less than 0.01 |
| Other                           | 0.786 (0.759 – 0.815) | Less than 0.01 | 0.743 (0.711 – 0.776) | Less than 0.01 |
| <b>Insurance Status</b>         |                       |                |                       |                |
| Uninsured (Ref.)                |                       |                |                       |                |
| Private                         | 1.479 (1.410 – 1.552) | Less than 0.01 | 1.413 (1.335 – 1.497) | Less than 0.01 |
| Medicare                        | 0.840 (0.802 – 0.881) | Less than 0.01 | 1.337 (1.262 – 1.416) | Less than 0.01 |
| <b>Income</b>                   |                       |                |                       |                |
| <38,000 (Ref.)                  |                       |                |                       |                |
| 38,000 - 47,900                 | 1.080 (1.052 – 1.109) | Less than 0.01 | 1.073 (1.041 – 1.107) | Less than 0.01 |
| 48,000 – 63,900                 | 1.086 (1.058 – 1.114) | Less than 0.01 | 1.061 (1.063 – 1.130) | Less than 0.01 |
| >63,000                         | 1.079 (1.052 – 1.106) | Less than 0.01 | 1.061 (1.028 – 1.094) | Less than 0.01 |
| <b>Education</b>                |                       |                |                       |                |
| >17.6 (Ref.)                    |                       |                |                       |                |
| 10.9-17.5%                      | 1.164 (1.135 – 1.194) | Less than 0.01 | 1.197 (0.128 – 0.134) | Less than 0.01 |
| 6.3-10.8%                       | 1.228 (1.198 – 1.258) | Less than 0.01 | 1.293 (0.128 – 0.134) | Less than 0.01 |
| <6.3%                           | 1.275 (1.198 – 1.258) | Less than 0.01 | 1.344 (0.128 – 0.134) | Less than 0.01 |
| <b>Population type</b>          |                       |                |                       |                |
| Metro (Ref.)                    |                       |                |                       |                |
| Urban                           | 1.062 (1.037 – 1.088) | Less than 0.01 | 1.218 (1.183 – 1.255) | Less than 0.01 |
| Rural                           | 1.138 (1.068 – 1.213) | Less than 0.01 | 1.420 (1.317 – 1.531) | Less than 0.01 |
| <b>Cancer Type</b>              |                       |                |                       |                |
| Rectum (vs Colon)               | 0.484 (0.476 – 0.492) | Less than 0.01 | 0.666 (0.613 – 0.587) | Less than 0.01 |
| <b>Multimodal Therapy</b>       |                       |                |                       |                |
| Need multimodal therapy         | 0.156 (0.153 – 0.159) | Less than 0.01 | 0.131 (0.128 – 0.134) | Less than 0.01 |

## Results



**Figure 2. Understanding Colon and Rectal Cancer.**  
 Cancer staging uses the TNM system. If/how far the tumor has grown, if cancer is present in lymph nodes and if the cancer has spread (metastasis.) Both Colon and Rectal cancers have 5 stages (0-4.)  
**Colon Cancer:**  
 Stage 1: cancer has grown into the second or third layer of the colon wall. Stage 2: cancer has grown into or past the fourth layer of the colon wall. Stage 3: cancer has spread from the colon to nearby lymph node.  
**Rectal cancer:**  
 Stage 1 cancer has invaded the submucosa or muscularis propia of the rectal wall. Stage 2 cancer has grown past rectal wall and possible invasion of nearby structures/ tissues. Stage 3 cancer has spread to nearby lymph node but not areas far from the rectum.

NCCN Guidelines® for Colon Cancer, Rectal Cancer, Version 2.2021 – January 21, 2021.

| Table 1. NCDB Demographics         | Sub-optimal completion of recommended therapies | Completion of all recommended therapies | p value                 |
|------------------------------------|---|---|-------------------------|
| <b>Cancer type</b>                 |   |   | Less than 0.01          |
| Colon                              | 46.6%   | 64.8%                                   |                         |
| Rectum                             | 53.4%   | 35.2%                                   |                         |
| <b>Multimodal therapy needed</b>   |   |   | Less than 0.01          |
| Multimodal therapy                 | 78.8%   | 36.9%                                   |                         |
| <b>Age</b>                         |   |   | Less than 0.01          |
| Age - mean or median (SD or 95%CI) | 70.6  | 65.5                                    |                         |
| <b>Sex</b>                         |   |   | 0.34                    |
| Male - n                           | 53.6%   | 53.4%                                   |                         |
| <b>Race</b>                        |   |   | 2.76 x10 <sup>-45</sup> |
| Race - White - n(%)                | 82.7%   | 84.9%                                   |                         |
| Race - Black                       | 11.2%   | 10.2%                                   |                         |
| Race - Other                       | 6.1%  | 4.8%                                    |                         |
| <b>Insurance Status</b>            |   |   | Less than 0.01          |
| Private                            | 27.1%   | 39.3%                                   |                         |
| Medicare                           | 67.2%   | 55.8%                                   |                         |
| Uninsured                          | 3.27%   | 3.21%                                   |                         |
| <b>Income</b>                      |   |   | 1.14x <sup>-10</sup>    |
| <38,000                            | 18.6%   | 17.5%                                   |                         |
| 38,000 - 47,900                    | 23.7%   | 24.1%                                   |                         |
| 48,000 – 63,900                    | 26.2%   | 26.7%                                   |                         |

| Table 3. Local Data     | Rural  | Urban  | p value        |
|-------------------------|--------|--------|----------------|
| 478 total patients      |        |        |                |
| Guideline adherent care | 82.30% | 71.10% | less than 0.02 |
| Need for MMT            | 63%    | 82%    | less than 0.02 |
| Received MMT            | 78%    | 66%    | less than 0.02 |

- Completion of recommended therapies favored rectal cancer patients who traveled from an urban area to another urban area to receive care: 71% local urban population vs 88% traveled- urban vs 79% traveled- rural.

## Conclusions

- Nationally, as supported by NCDB data, the healthcare barrier for inner-city patients outweighs the barrier of distance for rural patients, as the odds for completion of recommended therapy for rural patients was increased.
- On a local level, rural patients demonstrated lower median survival in comparison to urban counterparts. However, when guideline adherent care is optimal median survival is partially corrected.
- Moreover, when comparing guideline-adherent care amongst rural and urban populations in Kentucky, our study indicates that urban-living Kentuckians with colorectal cancer receive sub-optimal care.

Table 1.

- Colon cancer patients are 64% more likely to complete all recommended therapies.
- If multimodal therapy is needed patients are less likely to complete all recommended therapies.
- Minority patients are at a disadvantage in comparison to white patients in both sub-optimal and completion of all recommended therapies.
- The median distance traveled of those completed therapy and sub-optimal completion are comparable 8.1 vs 8.7.

Table 2.

- There are increased odds of completing all recommended therapies for those that
- Are diagnosed with rectal cancer
- Receiving care at comprehensive community center
- Identify as white
- Have private insurance
- have an income between \$38000 – \$47900
- Are from a rural area

Table 3:

- Rural Kentucky patients receive enhanced guideline adherent care. (82.3%)
- Rural patients more frequently needed MMT due to higher staging. (78%)

## Future directions

- Investigate barriers that impede urban patients from receiving guideline adherent care.
- Understand varying factors that are present when receiving care in an urban area. Investigate if factors have differing influence on urban and rural populations.

## Acknowledgements

Research was supported by the University of Louisville Cancer Education Program and the NIH/NCI (R25-CA134283) grant